INSIGHTS TOPIC

White-label and build versus buy

Editorial header: Outsourced RPM or in-house: what the 2027 proposal changes

White-label and build versus buy

Outsourced RPM or in-house: what the 2027 proposal changes

The proposed 2027 RPM policy makes employment arrangements a planning question when comparing outsourced and in-house programs. It does not make a delivery model compliant simply because it is called in-house, or make software licensing the same thing as outsourced clinical services.

Read article
Editorial header: White-label RPM: build, license or buy a platform

White-label and build versus buy

White-label RPM: build, license or buy a platform

White-label RPM buyers should compare building, licensing and acquisition by the rights, responsibilities and operating work each option creates. Choose a model after testing the patient-to-clinician workflow and reviewing the contract scope. A branded interface alone does not answer questions about clinical staffing, data access or ongoing platform maintenance.

Read article